КАНДИДЕМИЯ У ОНКОЛОГИЧЕСКИХ БОЛЬНЫХ: ОСОБЕННОСТИ ТАКСОНОМИЧЕСКОЙ СТРУКТУРЫ

Целью исследования было определение основных видов Candida, выделяемых из крови пациентов онкологического стационара, сравнение таксономической структуры штаммов, полученных при кандидемии у детей и взрослых. Всего за исследуемый период микробиологически (метод гемокультур) доказана кандидемия у 81 больного (повторы исключены), из них 29 (35,8%) - пациенты отделения реанимации и интенсивной терапии (ОРИТ). Общее количество изолятов, включенных в разработку, составило 82 штамма Candida spp. (10 видов). В целом в таксономической структуре кандидемий лидирует С. parapsilosis (60,97%), на втором месте - C. albicans (20,7%), на третьем - C. glabrata и C. lusitaniae - по 3,7% каждый вид, на четвертом - C. krusei, C. guilliermondii и C. tropicalis (по 2,4% каждый вид). C. parapsilosis статистически значимо чаще были выделены из крови по сравнению с C. albicans (61,0% против 20,7%, соответственно, p<0,0001). Кандидемия была выявлена статистически значимо чаще у взрослых по сравнению с детьми (63,0% против 37,0%, соответственно, p<0,002). Причем у взрослых статистически достоверно чаще из крови были выделены С. parapsilosis нежели C. albicans (70,6% против 15,7%, соответственно, p<0,0001). У детей достоверных различий в частоте выделения С. parapsilosis и C. albicans не выявлено: доля С. parapsilosis составила 45,2%, C. albicans - 29,0%. Редкие виды у взрослых были выделены в 7,8% случаев, у детей - в 12,9% случаев, но статистически значимых различий по этому параметру выявлено не было. Доля Candida non-albicans составила в целом за исследуемый период 79,3%, и основным видом в этой группе является C. parapsilosis (76,9%).

Kett D.H., Azoulay E., Echeverria P.M., Vincent J.L. Extended Prevalence of infection in ICUSGOI. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit. Care Med. 2011; 39(4): 665-70. https://doi.org/10.1097/CCM.0b013e318206c1ca

Bassetti M., Giacobbe D.R., Vena A., Trucchi C., Ansaldi F., Antonelli M. et al. Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Crit. Care. 2019; 23(1): 219. https://doi.org/10.1186/s13054-019-2497-3

Koehler P., Stecher M., Cornely O.A. Morbidity and mortality of candidaemia in Europe: An epidemiologic meta-analysis. Clin. Microbiol. Infect. 2019; 25: 1200-12. https://doi.org/10.1016/j.cmi.2019.04.024

Schroeder M., Weber T., Denker T., Winterland S., Wichmann D., Rohde H., Ozga A.-K., Fischer M. Kluge S. Epidemiology, clinical characteristics, and outcome of candidemia in critically ill patients in Germany: a single-center retrospective 10-year analysis. Ann.Intensive Care. 2020; 10: 142. https://doi.org/10.1186/s13613-020-00755-8

Tsay S.V., Mu Y., Williams S., Epson E., Nadle J., Bamberg W.M., Barter D.M. et al. Burden of candidemia in the United States 2017. Clin.Infect. Dis. 2020 Dec 3; 71(9): e449-e453. https://doi.org/10.1093/cid/ciaa193

Luzzati R., Merelli M., Ansaldi F., Rosin C., Azzini A., Cavinato S. et al. Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study. Infection. 2016; 44(6): 747-55. https://doi.org/10.1007/s15010-016-0924-9

Schwab F., Geffers C., Behnke M., Gastmeier P. ICU mortality following ICU-acquired primary bloodstream infections according to the type of pathogen: a prospective cohort study in 937 Germany ICUs (2006-2015). PLoS ONE. 2018; 13(3): e0194210. https://doi.org/10.1371/journal.pone.0194210

Шагдилеева Е.В., Рауш Е.Р., Богомолова Т.С., Васильева Н.В., Климко Н.Н. Результаты исследования инвазивного кандидоза в Санкт-Петербурге. Проблемы медицинской микологии. 2015; 17(2): 148-9

Carmon M., Rimon B., Freund H.R. Candida sepsis during total parenteral nutrition: An endogenous infection indicating the severity of patients’ disease state. Clin Nutr. 1992 Aug; 11(4): 240-3. https://doi.org/10.1016/0261-5614(92)90033-m

Pongrácz J., Juhász E., Iván M., Kristóf K. Significance of yeasts in bloodstream infection: Epidemiology and predisposing factors of Candidaemia in adult patients at a university hospital (2010-2014). Acta Microbiol. Immunol. Hung. 2015 Sep; 62(3): 317-29. https://doi.org/10.1556/030.62.2015.3.9

Tadec L., Talarmin J.P., Gastinne T., Bretonnière C., Miegeville M., Le Pape P., Morio F. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study. Mycoses. 2016 May; 59(5): 296-303. https://doi.org/10.1111/myc.12470

Nucci M., Anaissie E. Revisiting the source of candidemia: Skin or gut? Clin. Infect. Dis. 2001; 33(12): 1959-67. https://doi.org/10.1086/323759

Pammi M., Holland L., Butler G., Gacser A., Bliss J.M. Candida parapsilosis is a significant neonatal pathogen: A systematic review and meta-analysis. Pediatr. Infect. Dis. J. 2013; 32(5): e206-e216. https://doi.org/10.1097/INF.0b013e3182863a1c

Kullberg B.J., Arendrup M.C. Invasive Candidiasis. N. Engl. J. Med. 2015 Oct 08; 373(15): 1445-56. https://doi.org/10.1056/NEJMra1315399

Li D., Xia R., Zhang Q., Bai C., Li Z., Zhang P. Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China: An 8-year case-control study. BMC Infect. Dis. 2017; 17: 536. https://doi.org/10.1186/s12879-017-2636-x

McCarthy M.W., Walsh T.J. Prophylactic measures during induction for acute myeloid leukemia. Curr. Oncol. Rep. 2017; 19(3): 18. https://doi.org/10.1007/s11912-017-0574-9

Lausch K.R., Schultz D.K.H., Callesen M.T. Pediatric candidemia epidemiology and morbidities: A nationwide cohort. Pediatr. Infect. Dis. J. 2019; 38(5): 464-9. https://doi.org/10.1097/INF.0000000000002207

Novosad S.A., Fike L., Dudeck M.A., Allen-Bridson K., Edwards J.R., Edens C. et al. Pathogens causing central-line-associated bloodstream infections in acute-care hospitals-United States, 2011-2017. Infect. Control Hosp. Epidemiol. 2020; 41(3): 313-9. https://doi.org/10.1017/ice.2019.303

Warris A., Pana Z.D., Oletto A., Lundin R., Castagnola E., Lehrnbecher T., Groll A.H., Roilides E. Etiology and outcome of candidemia in neonates and children in Europe: An 11-year multinational retrospective study. Pediatr. Infect. Dis. J. 2020; 39: 114-20. https://doi.org/10.1097/INF.0000000000002530

Poissy J., Damonti L., Bignon A., Khanna N., Kietzell M. V., Boggian K. et al. The FUNGINOS and Allfun French Study Groups. Risk factors for candidemia: a prospective matched case-control study. Critical Care. 2020; 24(1): 2-11. https://doi.org/10.1186/s13054-020-2766-1

Andres L., Carpio M., Climaco A. Fungemia Candidiasis. Last Update: August 12, 2021. Avaible from: https://www.ncbi.nlm.nih.gov/books/NBK436012/#article-18810.s4

Li Y., Du M., Chen L.A., Liu Y., Liang Z. Nosocomial Bloodstream Infection Due to Candida spp. in China: Species Distribution, Clinical Features, and Outcomes. Mycopathologia. 2016 Aug; 181(7-8): 485-95. https://doi.org/10.1007/s11046-016-9997-3 Epub. 2016 Mar 19].

Fournier P., Schwebel C., Maubon D., Vesin A., Lebeau B., Foroni L. et al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J. Antimicrob. Chemother. 2011; 66: 2880-6. https://doi.org/10.1093/jac/dkr39

Bailly S., Maubon D., Fournier P., Pelloux H., Schwebel C., Chapuis C. et al. Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. - Trends over 10 years. J. Infect. 2016 Jan; 72(1): 103-11. https://doi.org/10.1016/j.jinf.2015.09.041 Epub. 2015 Oct 28. PMID: 26518058.

Pfaller M., Neofytos D., Diekema D., Azie N., Meier-Kriesche H.U., Quan S.P. et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004-2008. Diagn. Microbiol. Infect. Dis. 2012; 74(4): 323-31. https://doi.org/10.1016/j.diagmicrobio.2012.10.003

Montagna M.T., Caggiano G., Lovero G., De Giglio O., Coretti C., Cuna T. et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection. 2013; 41(3): 645-53. https://doi.org/10.1007/s15010-013-0432-0

Багирова Н.С., Дмитриева Н.В. Кандидемия у онкологических больных: таксономическая структура и резистентность к флуконазолу и вориконазолу in vitro. Лабораторная служба. 2017; 6 (3): 182-9. https://doi.org/10.17116/labs201763182-189

Blot S., Janssens R., Claeys G., Hoste E., Buyle F., De Waele J.J. et al. Effect of fluconazole consumption on long-term trends in candidal ecology. J. Antimicrob. Chemother. 2006; 58: 474-7. https://doi.org/10.1093/jac/dkl241

Lortholary O., Desnos-Ollivier M., Sitbon K., Fontanet A., Bretagne S., Dromer F. et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2441 patients. Antimicrob. Agents Chemotherapy. 2011; 55(2): 532-8. https://doi.org/10.1128/AAC.01128-10

McCarthy M.W., Walsh T.J. Candidemia in the cancer patient: Diagnosis, treatment, and future directions. Expert Rev. Anti-Infect. Ther. 2018; 16: 849-54. https://doi.org/10.1080/14787210.2018.1536546

Vasileiou E., Paisiou A., Tsipou C., Pourtsidis A., Galani V., Katzilakis N. et al. Candidemia in Children with Malignancies: Report from the Infection Working Group of the Hellenic Society of Pediatric Hematology-Oncology. J. Fungi. 2020; 6: 276. https://doi.org/10.3390/jof6040276

Siopi M., Tarpatzi A., Kalogeropoulou E., Damianidou S., Vasilakopoulou A., Vourli S. et al. Epidemiological Trends of Fungemia in Greece with a Focus on Candidemia during the Recent Financial Crisis: a 10-Year Survey in a Tertiary Care Academic Hospital and Review of Literature. Antimicrob. Agents Chemother. 2020 Feb 21; 64(3): e01516-9. https://doi.org/10.1128/AAC.01516-19

Risum M., Astvad K., Johansen H.K., Schønheyder H.C., Rosenvinge F., Knudsen J.D. et al. Update 2016-2018 of the Nationwide Danish Fungaemia Surveillance Study: Epidemiologic Changes in a 15-Year Perspective. J. Fungi. 2021; 7: 491. https://doi.org/10.3390/jof7060491

Doi A.M., Pignatari A.C.C., Edmond M.B., Marra A.R., Camargo L.F.A., Siqueira, R.A. et al. Epidemiology and Microbiologic Characterization of Nosocomial Candidemia from a Brazilian National Surveillance Program. PLoS ONE. 2016; 11(1): e0146909. https://doi.org/10.1371/journal.pone.0146909

Toda M., Williams S.R., Berkow E.L., Farley M.M., Harrison L.H., Bonner L. et al. Population-Based Active Surveillance for Culture-Confirmed Candidemia - Four Sites, United States, 2012-2016. MMWR Surveill. Summ. 2019; 6(8): 1-15. https://doi.org/10.15585/mmwr.ss6808a1

Santolaya M.E., Thompson L., Benadof D., Tapia C., Legarraga P., Cortés C. et al. A prospective, multi-center study of candida bloodstream infections in Chile. PLoS ONE. 2019; 14(3): e0212924. https://doi.org/10.1371/journal.pone.0212924

Zhang A.Y., Shrum S., Williams S., Petnic S., Nadle J., Johnston H. et al. The Changing Epidemiology of Candidemia in the United States: Injection Drug Use as an Increasingly Common Risk Factor - Active Surveillance in Selected Sites, United States, 2014-2017. Clin. Infect. Dis. 2019; 71(7): 1732-7. https://doi.org/10.1093/cid/ciz1061

Asmundsdottir L.R., Erlendsdottir H., Gottfredsson M. Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011. J. Clin. Microbiol. 2013; 51(3): 841-8. https://doi.org/10.1128/JCM.02566-12

Hesstvedt L., Gaustad P., Andersen C.T., Haarr E., Hannula R., Haukland H.H. et al. Twenty-two years of candidaemia surveillance: Results from a Norwegian national study. Clin. Microbiol. Infect. 2015; 21: 938-45. https://doi.org/10.1016/j.cmi.2015.06.008

Klingspor L., Ullberg M., Rydberg J., Kondori N., Serrander L., Swanberg J. et al. Epidemiology of fungaemia in Sweden: A nationwide retrospective observational survey. Mycoses. 2018; 61(10): 777-85. https://doi.org/10.1111/myc.12816

Ala-Houhala M., Valkonen M., Kolho E., Friberg N., Anttila V.J. Clinical and microbiological factors associated with mortality in candidemia in adult patients 2007-2016. Infect. Dis. 2019; 51(11): 824-30. https://doi.org/10.1080/23744235.2019.1662941

Blot S., Vandewoude K., Hoste E., Poelaert J., Colardyn F. Outcome in critically ill patients with candidal fungaemia: Candida albicans vs Candida glabrata. J. Hosp. Infect. 2001; 47(4): 308-13. https://doi.org/10.1053/jhin.2000.0918

Goemaere B., Becker P., Van Wijngaerden E., Maertens J., Spriet I., Hendrickx M., Lagrou K. Increasing candidaemia incidence from 2004 to 2015 with a shift in epidemiology in patients preexposed to antifungals. Mycoses. 2018 Feb; 61(2): 127-33. https://doi.org/10.1111/myc.12714 Epub 2017 Nov 15. PMID: 29024057.